As this series has outlined, peptides do not exist in a regulatory gray area. When used therapeutically, they are regulated as drugs regardless of how they are marketed.
For business owners and medical directors, peptide compliance does not need to be complicated, but it does need to be disciplined. The following four considerations frame the key considerations involved in adding or expanding peptide services.
This article is part of a four-part series examining the legal framework surrounding peptide programs in medical spas and wellness practices, including:
- Part 1 – What Are Peptides and How Are They Administered?
- Part 2 – Does the Corporate Practice of Medicine Apply to Peptides?
- Part 3 – State Laws That Impact Peptide Use in Wellness Centers
- Part 4 – Legal and Compliance Considerations for Peptides in Wellness Practices
1. Peptides Use is the Practice of Medicine
When peptides are used to diagnose, treat, mitigate, or prevent a condition, regulators view that service as the practice of medicine.
This means:
- Clinical decisions must be based on independent medical judgment.
- Patients cannot dictate whether a peptide is appropriate.
- Business owners cannot override medical provider discretion.
- Legal guidance cannot be delegated to bulk suppliers or compounding pharmacies with a different risk profile.
Peptides are not consumer wellness products. They are medical interventions. Every prescribing decision must be supported by evidence and rooted in professional medical judgment, based on the standard of care as directed by the state medical and nursing boards. When that framework is clear, the business model can be built around compliance.
2. Evaluate the Legal Status of Peptides Before Use
Consideration begins with the compound itself. Each peptide requires an individualized review of its federal classification and clinical profile.
That review focuses on several core factors:
- Federal Drug and Food Administration (“FDA”) approval status.
- Whether the intended use is on‑label, off‑label, complementary and alternative medicine, or experimental.
- The availability and quality of safety and efficacy data.
- Whether the proposed route of administration is clinically appropriate and supported by evidence.
For example, an FDA‑approved drug such as Tesamorelin carries a defined indication and an established regulatory framework. Other peptides commonly discussed in wellness settings may lack FDA approval or meaningful supporting data. That distinction carries direct compliance consequences. This initial compliance review should occur before a peptide is purchased, promoted, or added to a treatment menu. Once the peptide’s regulatory profile is clearly defined, the next step is to evaluate how applicable state law governs its use.
3. Peptide Use is Governed by State-Specific Laws
Federal classification is only part of the story. State law ultimately governs whether and how a peptide may be prescribed, administered, and delegated.
That assessment focuses on several state‑specific questions:
- Whether the intended on‑label or off‑label use is permitted.
- Whether complementary and alternative medicine pathways are recognized.
- What limitations apply to experimental or investigational use.
- What documentation, consent, or disclosure obligations apply.
Compliance with state‑specific requirements is critical to managing legal and professional risk. A model that may be defensible in one jurisdiction can create regulatory exposure in another. Once the intended use is confirmed as legally permissible, the next step is to evaluate who is authorized under state law to administer it to patients.
4. Assess Peptide Administration Permissions and Delegation Requirements
The route of administration is not just a clinical decision. It is a regulatory one.
State law governs who may prescribe a peptide (such as a physician, physician assistant, or nurse practitioner), who may administer it, and what level of supervision is required. Injectable therapies often trigger more restrictive delegation and supervision rules than oral, nasal, or topical formulations.
Before launching a peptide service, you should confirm:
- Who may clear the patient to make sure they are a good candidate for the medical treatment.
- Which license types are authorized to administer it.
- What delegation and supervision requirements apply.
- Whether protocols and standing orders are permissible.
Assumptions based on vendor materials or how other practices operate can create exposure. Authority to administer peptides must be grounded in state‑specific delegation laws, not industry custom. Even when delegation is properly structured, a broader compliance principle underlies every peptide decision. Taken together, these considerations highlight why peptide services should be evaluated holistically, not piecemeal, before they are offered or expanded.
ByrdAdatto Can Help You Navigate Peptide Service Line Compliance
Evaluating peptide services requires more than clinical interest. It requires careful compliance assessment before implementation or expansion. Our legal team helps medical spas, wellness centers, and physician-led practices assess regulatory risk, align ownership and operational structures, and establish compliant policies for peptide programs and other emerging service lines. Contact ByrdAdatto to ensure your peptide program is positioned for growth while remaining compliant with applicable law.
